The effect of XXXX on urethral sphincter morphology.

@entity1 @entity2180 @entity322
INTRODUCTION AND HYPOTHESIS: The aim of the study was to determine whether a 6-week course of 5 mg of @entity2180 used to treat mixed @entity322 , produces measurable changes in the appearance of the urethral sphincter. METHODS: Twenty-six @entity1 undergoing treatment for mixed @entity322 were recruited from a urogynaecology unit after failing to improve with conservative treatments and bladder drill. All underwent dual channel subtracted cystometry, which showed mixed urodynamic stress @entity322 and detrusor overactivity. All @entity1 underwent a 3D transperineal ultrasound before @entity2180 therapy was started and after 6 weeks of treatment. The urethral length, width and volume of the smooth muscle and total sphincter volume were compared before and after the treatment. RESULTS: Clinically, 13 reported no improvement in either stress or urge @entity322 . Eight @entity1 reported improvement in their urgency symptoms but no benefit in their stress leakage. Four @entity1 reported resolution of both stress and urge @entity322 . One @entity1 reported worsening of her bladder symptoms. There was no significant change in the urethral length (p = 0.27), width (p = 0.50), volume of smooth muscle (p = 0.87) or total sphincter volume (p = 0.60) before and after treatment with @entity2180 . CONCLUSIONS: A 6-week course of @entity2180 resulted in no measurable changes in the appearance of the urethral sphincter.
